Home » Stocks » LGND

Ligand Pharmaceuticals Inc. (LGND)

Stock Price: $150.23 USD 1.35 (0.91%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 2.50B
Revenue (ttm) 186.42M
Net Income (ttm) -2.99M
Shares Out 16.19M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 26.25
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $150.23
Previous Close $148.88
Change ($) 1.35
Change (%) 0.91%
Day's Open 150.18
Day's Range 148.33 - 151.90
Day's Volume 110,836
52-Week Range 78.26 - 219.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

On Friday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Ligand Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared...

1 month ago - Investors Business Daily

Ligand Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 93 the day before. The post Ligand Pharmaceuticals Gets A Composite Rating Upgrade appeared first on Investo...

1 month ago - Investors Business Daily

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, t...

1 month ago - Business Wire

Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices ...

Other stocks mentioned: MAC, MNKKQ, SKT
1 month ago - Benzinga

Retail investors have been on the hunt for the most shorted stocks to buy in the market this week. Share prices have reached record levels due to a rally of short squeezes.

Other stocks mentioned: GME, ISUN, KOSS, SKT
2 months ago - Benzinga

The unusual biotech could be a bitter pill for short sellers to swallow.

Other stocks mentioned: GILD, GME, JAZZ, JNJ, MRK, NVS, PFE
2 months ago - The Motley Fool

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

2 months ago - Zacks Investment Research

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 128.17% over the past year to $1.62, which beat the estimat...

2 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparse...

Other stocks mentioned: TVTX
2 months ago - Business Wire

The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.

Other stocks mentioned: MDGL, NKTR
2 months ago - Seeking Alpha

One Of The Most Shorted Names In Biotech: Ligand Pharmaceuticals

2 months ago - Seeking Alpha

This week, Ligand Pharmaceuticals (NASDAQ:LGND) found itself at the center of unexpected attention. The second-most shorted company in the U.S. saw its shares rise from $120 to almost $200 as Reddit use...

2 months ago - InvestorPlace

New York, New York--(Newsfile Corp. - January 28, 2021) - Levi & Korsinsky, LLP, a national securities law firm that has recovered hundreds of millions of dollars for investors, announces that it has co...

2 months ago - Newsfile Corp

An extreme level of herd mentality led by Reddit's 3 million member strong WallStreetBets forum has sparked an epic rally in the most shorted stocks in the market. The forum, members of which refer to e...

Other stocks mentioned: AMCX, BBBY, FIZZ, GME, IRBT, MAC, PLCE ...
2 months ago - Business Insider

On Wednesday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97. The post Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 appeared f...

2 months ago - Investors Business Daily

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand's CEO John ...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Dru...

3 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to leverage...

3 months ago - Business Wire

Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success.

4 months ago - Seeking Alpha

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. T...

4 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administratio...

5 months ago - Business Wire

Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations.

5 months ago - Zacks Investment Research

Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

  Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.

5 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecas...

5 months ago - Business Wire

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

5 months ago - Zacks Investment Research

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long...

Other stocks mentioned: CTIC, CERC, ISEE
5 months ago - Insider Monkey

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, HRTX, ILMN, IONS, RGNX
5 months ago - InvestorPlace

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company's role in the manufacturing of Veklury® (remdesivir), Gilead Sciences' antiviral drug for the...

5 months ago - Business Wire

Our call of the day comes from a fourth-generation money manager who specializes in finding overlooked smaller companies.

Other stocks mentioned: CZR, EHTH
5 months ago - Market Watch

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today's virtual Investor Day event its senior management reviewed recent business progress and provided a...

5 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand's CEO John H...

5 months ago - Business Wire

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Other stocks mentioned: ASLN, LLY, PPD
6 months ago - Seeking Alpha

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 mill...

6 months ago - Business Wire

CHENGDU, China--(BUSINESS WIRE)--HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-...

6 months ago - Business Wire

President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an experimental antibody cocktail from Regeneron Pharmaceuticals (NASDAQ: RE...

6 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1...

6 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plu...

6 months ago - Business Wire

SAN DIEGO, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfen...

Other stocks mentioned: PFNX
6 months ago - Business Wire

LGND vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ALKS
6 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Capti...

6 months ago - Business Wire

Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

7 months ago - Zacks Investment Research

Ligand Acquisitions, And Other News: The Good, Bad And Ugly Of Biopharma

7 months ago - Seeking Alpha

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. L...

7 months ago - Business Wire

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treat... [Read more...]

Industry
Biotechnology
IPO Date
Nov 18, 1992
CEO
John Higgins
Employees
155
Stock Exchange
NASDAQ
Ticker Symbol
LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 221.14, which is an increase of 47.20% from the latest price.

Price Target
$221.14
(47.20% upside)
Analyst Consensus: Buy